Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone

R Dresner-Pollak1, M Mayer, D Hochner-Celiniker

  • 1Department of Internal Medicine, Hadassah University Hospital on Mount Scopus, Jerusalem, Israel.

Calcified Tissue International
|February 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes.

Journal of medical genetics·2003
Same author

Impaired response to insulin associated with protein kinase C in chronic fructose-induced hypertension.

Blood pressure·2003
Same author

Clinical neurokinesiology of spastic gait.

Bratislavske lekarske listy·2002
Same author

Treatment of cluster headache with topiramate: effects and side-effects in five patients.

Cephalalgia : an international journal of headache·2002
Same author

Regulation of cyclooxygenase activity and progesterone production in the rat corpus luteum by inducible nitric oxide synthase.

Reproduction (Cambridge, England)·2002
Same author

Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells.

Pflugers Archiv : European journal of physiology·2002

Early decreases in serum bone alkaline phosphatase (B-ALP) can predict bone mineral density (BMD) gains in postmenopausal women undergoing hormone replacement therapy (HRT). This marker helps monitor treatment effectiveness for preventing bone loss.

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Hormone replacement therapy (HRT) is used to prevent bone loss in postmenopausal women.
  • However, up to 20% of women do not show increased bone mineral density (BMD) with HRT.
  • Predicting treatment response is crucial for optimizing osteoporosis management.

Purpose of the Study:

  • To investigate if early changes in serum bone alkaline phosphatase (B-ALP) can predict long-term BMD changes in postmenopausal women receiving HRT.
  • To establish B-ALP as a potential monitoring tool for HRT efficacy.

Main Methods:

  • Ninety women within 1 year of menopause were randomized to continuous or sequential estrogen/progestin, or estrogen alone therapy.
  • Bone mineral density (BMD) at the spine and femoral neck was measured using DXA over 2 years.

Related Experiment Videos

  • Serum B-ALP levels were assessed at baseline and various time points.

    • Main Results:

    • HRT led to significant spine BMD gains and variable femoral neck BMD changes across treatment groups.
    • HRT was associated with BMD loss in 17.4% (spine) and 25.3% (femoral neck) of women.
    • A decrease in B-ALP of >= 50% at 6 months predicted the greatest spine BMD gain at 2 years, with high sensitivity and specificity.

    Conclusions:

    • Early reduction in serum B-ALP levels is a significant predictor of positive BMD response to HRT.
    • A 40% decrease in B-ALP at 6 months demonstrates high predictive value for spine BMD gain.
    • Serum B-ALP can serve as a valuable biomarker to monitor BMD response to HRT in postmenopausal women.